drugset / Trial / NCT00633022

A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

NCT00633022

Phase 2 Completed 99 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to assess the potential anti-inflammatory effects of a 3-month treatment with GW856553, on the inflammatory activity within the aorta and carotid plaques, as assessed by FDG-PET/CT.

Timeline

Start
2008-06-02
Primary completion
2009-12-03
Completion
2009-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Losmapimod Small molecule 7.5 mg Oral

Indications